105 related articles for article (PubMed ID: 28279716)
1. Expression of key mTOR pathway components in pancreatic ductal adenocarcinoma: A multicenter study for clinicopathologic and prognostic significance.
Zhou L; Yuan D; Zhang ZG; Liang ZY; Zhou WX; Yang JY; Jiang SH; Lu J; Zhang TP; You L; Guo JC; Zhao YP
Cancer Lett; 2017 Jun; 395():45-52. PubMed ID: 28279716
[TBL] [Abstract][Full Text] [Related]
2. The mTOR downstream regulator (p-4EBP1) is a novel independent prognostic marker in ovarian cancer.
Alabdullah ML; Ahmad DA; Moseley P; Madhusudan S; Chan S; Rakha E
J Obstet Gynaecol; 2019 May; 39(4):522-528. PubMed ID: 30712414
[TBL] [Abstract][Full Text] [Related]
3. Activation of mTOR signaling pathway associated with adverse prognostic factors of epithelial ovarian cancer.
No JH; Jeon YT; Park IA; Kim YB; Kim JW; Park NH; Kang SB; Han JY; Lim JM; Song YS
Gynecol Oncol; 2011 Apr; 121(1):8-12. PubMed ID: 21276607
[TBL] [Abstract][Full Text] [Related]
4. Activation of Akt/mTOR pathway is associated with poor prognosis of nasopharyngeal carcinoma.
Wang W; Wen Q; Xu L; Xie G; Li J; Luo J; Chu S; Shi L; Huang D; Li J; Fan S
PLoS One; 2014; 9(8):e106098. PubMed ID: 25165983
[TBL] [Abstract][Full Text] [Related]
5. Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer.
Castellvi J; Garcia A; Rojo F; Ruiz-Marcellan C; Gil A; Baselga J; Ramon y Cajal S
Cancer; 2006 Oct; 107(8):1801-11. PubMed ID: 16983702
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical analysis of the mTOR pathway in intrahepatic cholangiocarcinoma.
Wang Z; Zheng T; Wu Q; Wang J; Wu C; Wang J
Neoplasma; 2012; 59(2):137-41. PubMed ID: 22248270
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical analysis of the mammalian target of rapamycin signalling pathway in extramammary Paget's disease.
Chen S; Nakahara T; Uchi H; Takeuchi S; Takahara M; Kido M; Dugu L; Tu Y; Moroi Y; Furue M
Br J Dermatol; 2009 Aug; 161(2):357-63. PubMed ID: 19438435
[TBL] [Abstract][Full Text] [Related]
8. High Phosphorylation Status of AKT/mTOR Signal in DESI2-Reduced Pancreatic Ductal Adenocarcinoma.
Shen CC; Cui XY; He Y; Kang YH; Yi C; Yang JL; Gou LT
Pathol Oncol Res; 2015 Apr; 21(2):267-72. PubMed ID: 25079376
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical and molecular analysis of PI3K/AKT/mTOR pathway in esophageal carcinoma.
Tasioudi KE; Sakellariou S; Levidou G; Theodorou D; Michalopoulos NV; Patsouris E; Korkolopoulou P; Saetta AA
APMIS; 2015 Aug; 123(8):639-47. PubMed ID: 25912437
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathologic features and prognostic implications of MYBL2 protein expression in pancreatic ductal adenocarcinoma.
Yu R; Li C; Lin X; Chen Q; Li J; Song L; Lin L; Liu J; Zhang Y; Kong W; Ouyang X; Chen X
Pathol Res Pract; 2017 Aug; 213(8):964-968. PubMed ID: 28559119
[TBL] [Abstract][Full Text] [Related]
11. 4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis.
Rojo F; Najera L; Lirola J; Jiménez J; Guzmán M; Sabadell MD; Baselga J; Ramon y Cajal S
Clin Cancer Res; 2007 Jan; 13(1):81-9. PubMed ID: 17200342
[TBL] [Abstract][Full Text] [Related]
12. A comprehensive immunohistochemical approach of AKT/mTOR pathway and p-STAT3 in mycosis fungoides.
Levidou G; Siakantaris M; Papadaki T; Papadavid E; Vassilakopoulos TP; Angelopoulou MK; Marinos L; Nikolaou V; Economidi A; Antoniou C; Patsouris E; Korkolopoulou P
J Am Acad Dermatol; 2013 Sep; 69(3):375-84. PubMed ID: 23685026
[TBL] [Abstract][Full Text] [Related]
13. [PI3K-Akt/LKB1-AMPK-mTOR-p70S6K/4EBP1 signaling pathways participate in the regulation of testis development and spermatogenesis: An update].
Duan P; Quan C; Huang WT; Yang KD
Zhonghua Nan Ke Xue; 2016 Nov; 22(11):1016-1020. PubMed ID: 29281211
[TBL] [Abstract][Full Text] [Related]
14. Phosphorylated 4E-binding protein 1 (p-4E-BP1): a novel prognostic marker in human astrocytomas.
Korkolopoulou P; Levidou G; El-Habr EA; Piperi C; Adamopoulos C; Samaras V; Boviatsis E; Thymara I; Trigka EA; Sakellariou S; Kavantzas N; Patsouris E; Saetta AA
Histopathology; 2012 Aug; 61(2):293-305. PubMed ID: 22690797
[TBL] [Abstract][Full Text] [Related]
15. Phosphorylated mTOR expression correlates with podoplanin expression and high tumor grade in esophageal squamous cell carcinoma.
Chuang WY; Chang YS; Chao YK; Yeh CJ; Ueng SH; Chang CY; Liu YH; Tseng CK; Chang HK; Wan YL; Hsueh C
Int J Clin Exp Pathol; 2015; 8(10):12757-65. PubMed ID: 26722465
[TBL] [Abstract][Full Text] [Related]
16. mTOR expression and activity patterns in gastroenteropancreatic neuroendocrine tumours.
Kasajima A; Pavel M; Darb-Esfahani S; Noske A; Stenzinger A; Sasano H; Dietel M; Denkert C; Röcken C; Wiedenmann B; Weichert W
Endocr Relat Cancer; 2011 Feb; 18(1):181-92. PubMed ID: 21159731
[TBL] [Abstract][Full Text] [Related]
17. Expression of the mammalian target of rapamycin pathway markers in lung adenocarcinoma and squamous cell carcinoma.
Kim HS; Kim GY; Lim SJ; Kim YW
Pathobiology; 2012; 79(2):84-93. PubMed ID: 22286903
[TBL] [Abstract][Full Text] [Related]
18. Reciprocal expression of p-AMPKa and p-S6 is strongly associated with the prognosis of gastric cancer.
Zheng Z; Zheng Y; Zhang M; Wang J; Yu G; Fang W
Tumour Biol; 2016 Apr; 37(4):4803-11. PubMed ID: 26520441
[TBL] [Abstract][Full Text] [Related]
19. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
20. Expression of phosphorylated mTOR and its regulatory protein is related to biological behaviors of ameloblastoma.
Li N; Zhong M; Song M
Int J Clin Exp Pathol; 2012; 5(7):660-7. PubMed ID: 22977662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
